Regeneron Pharmaceuticals is expected to report Q2 2026 revenue of $3.82 billion and EPS of $8.00, while the current stock price of $695.18 remains significantly below the average analyst target of $828.59.
Investors are primarily focused on the ophthalmology franchise's transition, specifically the uptake of Eylea HD as it faces increasing competition from Roche’s Vabysmo and upcoming biosimilars.
While blockbuster drug Dupixent continues to provide a stable foundation with estimated U.S. sales of $4.00 billion, analysts remain cautious regarding potential margin compression and the impact of fluctuating Eylea inventory levels. Recent clinical advances in oncology and a new $3 billion share repurchase program offer some support, but the core focus remains on stabilizing the Eylea revenue stream.